Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
accepted:
24
07
2023
medline:
1
11
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
ppublish
Résumé
A significant proportion of adults with major depressive disorder (MDD) do not respond to treatments which are currently used in clinical practice such as first-generation monoamine-based antidepressants. The objective of this systematic review was to assess the efficacy, safety, and mechanisms of action of AXS-05, a combination of the NMDA-receptor antagonist dextromethorphan with bupropion, in adults with MDD. We searched PubMed, Embase, Google Scholar, and ClinicalTrials.gov for current studies reporting on efficacy and/or safety of AXS-05 in patients with MDD. The search terms included: "AXS-05" OR "dextromethorphan and bupropion" AND "depression". Studies from database inception to January 2023 were evaluated. Risk of bias was assessed using the Cochrane Risk of Bias tool. The search yielded 54 studies of which 5 were included. All studies had low risk of bias. Depression severity, measured with the Montgomery-Åsberg Depression Rating Scale (MADRS) significantly decreased as early as 1-week post-treatment from baseline when compared to a placebo-controlled group (LS mean difference 2.2; 95% CI 0.6-3.9; p = 0.007) and at 2 weeks compared to an active control group (LS mean difference 4.7; 95% CI 0.6-8.8; p = 0.024). Treatment efficacy could be maintained for up to 12 months with mean MADRS score reduction of 23 points from baseline. Clinical remission and response rates also improved at week 1 and were maintained for 12 months. The treatment was well-tolerated, with some transient adverse events reported. Current evidence suggests that the combination of dextromethorphan and bupropion is a well-tolerated, rapid-acting treatment option for adults with MDD. Initial success with AXS-05 supports the mechanistic role of glutamatergeric and sigma 1 signaling in the pathophysiology of MDD.
Sections du résumé
BACKGROUND
A significant proportion of adults with major depressive disorder (MDD) do not respond to treatments which are currently used in clinical practice such as first-generation monoamine-based antidepressants.
OBJECTIVES
The objective of this systematic review was to assess the efficacy, safety, and mechanisms of action of AXS-05, a combination of the NMDA-receptor antagonist dextromethorphan with bupropion, in adults with MDD.
METHODS
We searched PubMed, Embase, Google Scholar, and ClinicalTrials.gov for current studies reporting on efficacy and/or safety of AXS-05 in patients with MDD. The search terms included: "AXS-05" OR "dextromethorphan and bupropion" AND "depression". Studies from database inception to January 2023 were evaluated. Risk of bias was assessed using the Cochrane Risk of Bias tool.
RESULTS
The search yielded 54 studies of which 5 were included. All studies had low risk of bias. Depression severity, measured with the Montgomery-Åsberg Depression Rating Scale (MADRS) significantly decreased as early as 1-week post-treatment from baseline when compared to a placebo-controlled group (LS mean difference 2.2; 95% CI 0.6-3.9; p = 0.007) and at 2 weeks compared to an active control group (LS mean difference 4.7; 95% CI 0.6-8.8; p = 0.024). Treatment efficacy could be maintained for up to 12 months with mean MADRS score reduction of 23 points from baseline. Clinical remission and response rates also improved at week 1 and were maintained for 12 months. The treatment was well-tolerated, with some transient adverse events reported.
CONCLUSION
Current evidence suggests that the combination of dextromethorphan and bupropion is a well-tolerated, rapid-acting treatment option for adults with MDD. Initial success with AXS-05 supports the mechanistic role of glutamatergeric and sigma 1 signaling in the pathophysiology of MDD.
Identifiants
pubmed: 37792265
doi: 10.1007/s40263-023-01032-5
pii: 10.1007/s40263-023-01032-5
doi:
Substances chimiques
Bupropion
01ZG3TPX31
Dextromethorphan
7355X3ROTS
Antidepressive Agents
0
Types de publication
Systematic Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
867-881Subventions
Organisme : NIA NIH HHS
ID : T32 AG019134
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG070666
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH117438
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317:1517. https://doi.org/10.1001/jama.2017.3826 .
doi: 10.1001/jama.2017.3826
pubmed: 28418491
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858. https://doi.org/10.1016/S0140-6736(18)32279-7 .
doi: 10.1016/S0140-6736(18)32279-7
Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiatry. 2016;61:510–23. https://doi.org/10.1177/0706743716659416 .
Maj M, Stein DJ, Parker G, Zimmerman M, Fava GA, De Hert M, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020;19:269–93. https://doi.org/10.1002/wps.20771 .
doi: 10.1002/wps.20771
pubmed: 32931110
pmcid: 7491646
Rhee TG, Steffens DC. Major depressive disorder and impaired health-related quality of life among US older adults. Int J Geriatr Psychiatry. 2020;35:1189–97. https://doi.org/10.1002/gps.5356 .
doi: 10.1002/gps.5356
pubmed: 32497391
McIntyre RS, Millson B, Power GS. Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: economic burden and healthcare resource utilization. J Affect Disord. 2020;277:30–8. https://doi.org/10.1016/j.jad.2020.07.045 .
doi: 10.1016/j.jad.2020.07.045
pubmed: 32791390
Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006;7:137–51. https://doi.org/10.1038/nrn1846 .
doi: 10.1038/nrn1846
pubmed: 16429123
Hermida AP, Glass OM, Shafi H, McDonald WM. Electroconvulsive therapy in depression: current practice and future direction. Psychiatr Clin North Am. 2018;41:341–53. https://doi.org/10.1016/j.psc.2018.04.001 .
doi: 10.1016/j.psc.2018.04.001
pubmed: 30098649
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, et al. Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta-analysis. JAMA Psychiat. 2022;79:1162–72. https://doi.org/10.1001/jamapsychiatry.2022.3352 .
doi: 10.1001/jamapsychiatry.2022.3352
McIntyre RS, Filteau M-J, Martin L, Patry S, Carvalho A, Cha DS, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7. https://doi.org/10.1016/j.jad.2013.10.043 .
doi: 10.1016/j.jad.2013.10.043
pubmed: 24314926
Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82:20m13699. https://doi.org/10.4088/JCP.20m13699 .
doi: 10.4088/JCP.20m13699
pubmed: 33989464
Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19:247. https://doi.org/10.1186/s12888-019-2222-4 .
doi: 10.1186/s12888-019-2222-4
pubmed: 31391065
pmcid: 6686569
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793–802. https://doi.org/10.1001/archgenpsychiatry.2010.90 .
doi: 10.1001/archgenpsychiatry.2010.90
pubmed: 20679587
pmcid: 3000408
Hofmann SG, Curtiss J, Carpenter JK, Kind S. Effect of treatments for depression on quality of life: a meta-analysis. Cogn Behav Ther. 2017;46:265–86. https://doi.org/10.1080/16506073.2017.1304445 .
doi: 10.1080/16506073.2017.1304445
pubmed: 28440699
pmcid: 5663193
McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30:515–27. https://doi.org/10.1002/da.22063 .
doi: 10.1002/da.22063
pubmed: 23468126
Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review and meta-analysis. J Psychiatr Res. 2022;151:693–709. https://doi.org/10.1016/j.jpsychires.2022.04.037 .
doi: 10.1016/j.jpsychires.2022.04.037
pubmed: 35688035
Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009–January 2019. J Affect Disord. 2020;277:831–41. https://doi.org/10.1016/j.jad.2020.09.007 .
doi: 10.1016/j.jad.2020.09.007
pubmed: 33065824
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178:383–99. https://doi.org/10.1176/appi.ajp.2020.20081251 .
doi: 10.1176/appi.ajp.2020.20081251
pubmed: 33726522
pmcid: 9635017
Yavi M, Lee H, Henter ID, Park LT, Zarate CA. Ketamine treatment for depression: a review. Discov Ment Health. 2022;2:9. https://doi.org/10.1007/s44192-022-00012-3 .
doi: 10.1007/s44192-022-00012-3
pubmed: 35509843
pmcid: 9010394
Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, et al. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opin Emerg Drugs. 2021;26:63–74. https://doi.org/10.1080/14728214.2021.1898588 .
doi: 10.1080/14728214.2021.1898588
pubmed: 33682569
Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1–22. https://doi.org/10.1016/j.pharmthera.2016.01.016 .
doi: 10.1016/j.pharmthera.2016.01.016
pubmed: 26826604
Hole K, Arnestad M, Molden E, Haslemo T. Dose-dependent inhibition of cYP2D6 by bupropion in patients with depression. J Clin Psychopharmacol. 2021;41:281–5. https://doi.org/10.1097/JCP.0000000000001387 .
doi: 10.1097/JCP.0000000000001387
pubmed: 33905640
O’Gorman C, Jones A, Tabuteau H. AXS-05 (Dextromethorphan/Bupropion): psychopharmacology and the potential for therapeutic application in the treatment of neuropsychiatric symptoms. Eur Neuropsychopharmacol. 2019;29:S458. https://doi.org/10.1016/j.euroneuro.2018.11.686 .
doi: 10.1016/j.euroneuro.2018.11.686
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928 .
doi: 10.1136/bmj.d5928
pubmed: 22008217
pmcid: 3196245
Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (Dextromethorphan-Bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022;179:490–9. https://doi.org/10.1176/appi.ajp.21080800 .
doi: 10.1176/appi.ajp.21080800
pubmed: 35582785
Iosifescu DV, Jones A, O’Gorman C, Streicher C, Feliz S, Fava M, et al. Efficacy and safety of AXS-05 (Dextromethorphan-Bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry. 2022;83:21m14345. https://doi.org/10.4088/JCP.21m14345 .
doi: 10.4088/JCP.21m14345
pubmed: 35649167
Jones A, O'Gorman C, Clayton AH, Tabuteau H. Analysis of Efficacy of AXS-05 in the Treatment of Major Depressive Disorder Based on Gender, Race, and Prior Antidepressant Use [Poster Presentation]. ISCTM Annual Meeting, New York, NY, USA; April 6-9 2021. https://isctm.org/public_access/17th_Annual/Poster/Jones_poster.pdf .
O'Gorman C, Jones A, Kennon K, Niecestro R, Iosifescu DV, Stahl S, et al. AXS-05 for Neuropsychiatric Disorders: Scientific Rationale and Clinical Development [Poster Presentation]. ASCP Annual Meeting, Miami Beach, FL, USA. May 29-June 1 2018. https://d3dyybxyjb4kyh.cloudfront.net/pdfs/Axsome_AXS_05_Poster_ASCP_5_2018.pdf .
O'Gorman C, Jones A, Tabuteau H. Sustained Efficacy with Long-term Treatment if AXS-05: Results from the COMET Phase 3 Trial, a Long-term, Open-label Study Evaluating the Efficacy and Safety of AXS-05 for the Treatment of MDD [Poster Presentation]. American Society of Clinical Psychopharmacology, Annual Meeting, New York, NY, USA. June 1-4 2021. https://d3dyybxyjb4kyh.cloudfront.net/pdfs/ASCP+2021+COMET+overall+poster+FINAL.pdf
Matveychuk D, Thomas RK, Swainson J, Khullar A, MacKay M-A, Baker GB, et al. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther Adv Psychopharmacol. 2020;10:2045125320916657. https://doi.org/10.1177/2045125320916657 .
doi: 10.1177/2045125320916657
pubmed: 32440333
pmcid: 7225830
Rodrigues NB, McIntyre RS, Lipsitz O, Cha DS, Lee Y, Gill H, et al. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: results from the Canadian Rapid Treatment Center of Excellence. J Affect Disord. 2020;276:570–5. https://doi.org/10.1016/j.jad.2020.07.083 .
doi: 10.1016/j.jad.2020.07.083
pubmed: 32871688
Siu A, Drachtman R. Dextromethorphan: a review of N-methyl-D-aspartate receptor antagonist in the management of pain. CNS Drug Rev. 2007;13:96–106. https://doi.org/10.1111/j.1527-3458.2007.00006.x .
doi: 10.1111/j.1527-3458.2007.00006.x
pubmed: 17461892
pmcid: 6494157
Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23–37. https://doi.org/10.1007/s00210-003-0832-2 .
doi: 10.1007/s00210-003-0832-2
pubmed: 14618296
Xue C, Zhang X, Cai W. Prediction of drug–drug interactions with bupropion and its metabolites as CYP2D6 inhibitors using a physiologically-based pharmacokinetic model. Pharmaceutics. 2017;10:1. https://doi.org/10.3390/pharmaceutics10010001 .
doi: 10.3390/pharmaceutics10010001
pubmed: 29267251
pmcid: 5874814
Garnock-Jones KP. Dextromethorphan/quinidine: in pseudobulbar affect. CNS Drugs. 2011;25:435–45. https://doi.org/10.1016/j.jad.2020.07.083 .
doi: 10.1016/j.jad.2020.07.083
pubmed: 21476614
Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016;164:170–82. https://doi.org/10.1016/j.pharmthera.2016.04.010 .
doi: 10.1016/j.pharmthera.2016.04.010
pubmed: 27139517
Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol. 1995;15:263–9. https://doi.org/10.1097/00004714-199508000-00005 .
doi: 10.1097/00004714-199508000-00005
pubmed: 7593709
Pechnick RN, Poland RE. Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004;309:515–22. https://doi.org/10.1124/jpet.103.060038 .
doi: 10.1124/jpet.103.060038
pubmed: 14742749
Miller SC. Dextromethorphan to dextrorphan: a pathway towards abuse liability. Hum Psychopharmacol. 2011;26:89–90. https://doi.org/10.1002/hup.1164 . (author reply 91).
doi: 10.1002/hup.1164
pubmed: 23055419
Schatzberg AF. Understanding the efficacy and mechanism of action of a dextromethorphan-bupropion combination: where does it fit in the NMDA versus mu-Opioid story? Am J Psychiatry. 2022;179:448–50. https://doi.org/10.1176/appi.ajp.20220434 .
doi: 10.1176/appi.ajp.20220434
pubmed: 35775155
Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol. 1998;18:332–7. https://doi.org/10.1097/00004714-199808000-00014 .
doi: 10.1097/00004714-199808000-00014
pubmed: 9690700
Schoedel KA, Morrow SA, Sellers EM. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatr Dis Treat. 2014;10:1161–74. https://doi.org/10.2147/NDT.S30713 .
doi: 10.2147/NDT.S30713
pubmed: 25061302
pmcid: 4079824
Zawertailo LA, Tyndale RF, Busto U, Sellers EM. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol. 2010;25:71–9. https://doi.org/10.1002/hup.1086 .
doi: 10.1002/hup.1086
pubmed: 20041473
Jones A, Anderson A, Tabuteau H. 40. Efficacy and safety of AXS-05 in the prevention of relapse in patients with treatment-resistant depression: results from the MERIT trial. In: Poster presented at: annual meeting of the American Psychiatric Association; 2022 May 20–24; New Orleans (LA).
Moriguchi S, Takamiya A, Noda Y, Horita N, Wada M, Tsugawa S, et al. Glutamatergic neurometabolite leve1ls in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol Psychiatry. 2019;24:952–64. https://doi.org/10.1038/s41380-018-0252-9 .
doi: 10.1038/s41380-018-0252-9
pubmed: 30315224
Onaolapo AY, Onaolapo OJ. Glutamate and depression: reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule. World J Psychiatry. 2021;11:297–315. https://doi.org/10.5498/wjp.v11.i7.297 .
doi: 10.5498/wjp.v11.i7.297
pubmed: 34327123
pmcid: 8311508
Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62:63–77. https://doi.org/10.1016/j.neuropharm.2011.07.036 .
doi: 10.1016/j.neuropharm.2011.07.036
pubmed: 21827775
Sarawagi A, Soni ND, Patel AB. Glutamate and GABA homeostasis and neurometabolism in major depressive disorder. Front Psychiatry. 2021;12:637863. https://doi.org/10.3389/fpsyt.2021.637863 .
doi: 10.3389/fpsyt.2021.637863
pubmed: 33986699
pmcid: 8110820
Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102:75–90. https://doi.org/10.1016/j.neuron.2019.03.013 .
doi: 10.1016/j.neuron.2019.03.013
pubmed: 30946828
pmcid: 6450409
Banasr M, Dwyer JM, Duman RS. Cell atrophy and loss in depression: reversal by antidepressant treatment. Curr Opin Cell Biol. 2011;23:730–7. https://doi.org/10.1016/j.ceb.2011.09.002 .
doi: 10.1016/j.ceb.2011.09.002
pubmed: 21996102
pmcid: 3259683
Adell A. Brain NMDA receptors in schizophrenia and depression. Biomolecules. 2020;10:947. https://doi.org/10.3390/biom10060947 .
doi: 10.3390/biom10060947
pubmed: 32585886
pmcid: 7355879
Chan SY, Matthews E, Burnet PWJ. ON or OFF? Modulating the N-Methyl-D-aspartate receptor in major depression. Front Mol Neurosci. 2016;9:169. https://doi.org/10.3389/fnmol.2016.00169 .
doi: 10.3389/fnmol.2016.00169
pubmed: 28133445
Sattar Y, Wilson J, Khan AM, Adnan M, Azzopardi Larios D, Shrestha S, et al. A review of the mechanism of antagonism of N-methyl-D-aspartate receptor by ketamine in treatment-resistant depression. Cureus. 2018;10:e2652. https://doi.org/10.7759/cureus.2652 .
doi: 10.7759/cureus.2652
pubmed: 30034974
pmcid: 6051558
Nguyen L, Matsumoto RR. Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. Behav Brain Res. 2015;295:26–34. https://doi.org/10.1016/j.bbr.2015.03.024 .
doi: 10.1016/j.bbr.2015.03.024
pubmed: 25804358
Amidfar M, Woelfer M, Réus GZ, Quevedo J, Walter M, Kim Y-K. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: evidence from translational research. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94:109668. https://doi.org/10.1016/j.pnpbp.2019.109668 .
doi: 10.1016/j.pnpbp.2019.109668
pubmed: 31207274
Zhou W, Wang N, Yang C, Li X-M, Zhou Z-Q, Yang J-J. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry. 2014;29:419–23. https://doi.org/10.1016/j.eurpsy.2013.10.005 .
doi: 10.1016/j.eurpsy.2013.10.005
pubmed: 24321772
Lee S-Y, Wang T-Y, Chen S-L, Chang Y-H, Chen P-S, Huang S-Y, et al. Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial. Int J Bipolar Disord. 2020;8:11. https://doi.org/10.1186/s40345-019-0174-8 .
doi: 10.1186/s40345-019-0174-8
pubmed: 32115672
pmcid: 7049537
Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS ONE. 2014;9:e89985. https://doi.org/10.1371/journal.pone.0089985 .
doi: 10.1371/journal.pone.0089985
pubmed: 24587167
pmcid: 3938562
Ren P, Wang J, Li N, Li G, Ma H, Zhao Y, et al. Sigma-1 receptors in depression: mechanism and therapeutic development. Front Pharmacol. 2022;13:925879. https://doi.org/10.3389/fphar.2022.925879 .
doi: 10.3389/fphar.2022.925879
pubmed: 35784746
pmcid: 9243434
Wang D, Noda Y, Tsunekawa H, Zhou Y, Miyazaki M, Senzaki K, et al. Role of N-methyl-D-aspartate receptors in antidepressant-like effects of sigma 1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA-4503) in olfactory bulbectomized rats. J Pharmacol Exp Ther. 2007;322:1305–14. https://doi.org/10.1124/jpet.107.124685 .
doi: 10.1124/jpet.107.124685
pubmed: 17556637
Fishback JA, Robson MJ, Xu Y-T, Matsumoto RR. Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther. 2010;127:271–82. https://doi.org/10.1016/j.pharmthera.2010.04.003 .
doi: 10.1016/j.pharmthera.2010.04.003
pubmed: 20438757
pmcid: 3993947
Mandelli L, Wang S-M, Han C, Lee S-J, Patkar AA, Masand PS, et al. The impact of a single nucleotide polymorphism in SIGMAR1 on depressive symptoms in major depressive disorder and bipolar disorder. Adv Ther. 2017;34:713–24. https://doi.org/10.1124/jpet.107.124685 .
doi: 10.1124/jpet.107.124685
pubmed: 28144920
Skuza G, Rogóz Z. Antidepressant-like effect of PRE-084, a selective sigma1 receptor agonist, in Albino Swiss and C57BL/6J mice. Pharmacol Rep. 2009;61:1179–83. https://doi.org/10.1016/s1734-1140(09)70181-1 .
doi: 10.1016/s1734-1140(09)70181-1
pubmed: 20081254
Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11:eaau5266. https://doi.org/10.1126/scitranslmed.aau5266 .
doi: 10.1126/scitranslmed.aau5266
pubmed: 30728287
pmcid: 6936250
Stahl SM. Dextromethorphan/Bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity. CNS Spectr. 2019;24:461–6. https://doi.org/10.1017/S1092852919001470 .
doi: 10.1017/S1092852919001470
pubmed: 31566163
Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6:159–66. https://doi.org/10.4088/pcc.v06n0403 .
doi: 10.4088/pcc.v06n0403
pubmed: 15361919
pmcid: 514842
Dhir A, Kulkarni SK. Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor. Fundam Clin Pharmacol. 2008;22:387–94. https://doi.org/10.1111/j.1472-8206.2008.00605.x .
doi: 10.1111/j.1472-8206.2008.00605.x
pubmed: 18705749
Bagdas D, AlSharari S, Roni MA, Campbell VC, Muldoon PP, Carroll FI, et al. Blockade of nicotinic acetylcholine receptor enhances the responsiveness to bupropion in the mouse forced swim test. Behav Brain Res. 2019;360:262–9. https://doi.org/10.1016/j.bbr.2018.12.027 .
doi: 10.1016/j.bbr.2018.12.027
pubmed: 30552947